OUR TECHNOLOGY IS BASED ON CUTTING-EDGE SCIENTIFIC RESEARCH FROM THE UNIVERSITY OF CINCINNATI.
Hoth Therapeutics is a development stage biopharmaceutical company focused on proprietary therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema. To treat indications impacting more than 32 million Americans, Hoth is working to develop and commercialize the BioLexa™ Platform, a proprietary, patented, drug compound platform developed at the University of Cincinnati. The BioLexa Platform has achieved positive results at preclinical studies conducted at the University of Miami.
Hoth Therapeutics is a development-stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema.
Hoth owns the exclusive rights to develop the BioLexa PlatformTM for all indications in humans. The BioLexa PlatformTM is a proprietary, patented, drug compound platform developed at the University of Cincinnati. The BioLexa PlatformTM combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups by preventing the formation of infectious biofilms and the resulting clogging of sweat ducts. It is the first product candidate intended to prevent the symptom-triggering flare-ups rather than simply treating symptoms after they occur.
We intend to explore the use of the BioLexa PlatformTM for the treatment of atopic dermatitis, or eczema.
We also intend to explore the use of the BioLexa PlatformTM in the aesthetic dermatology field to help treat and reduce post-procedure infections, accelerate healing and improve clinical outcomes for patients undergoing procedures. We believe that the BioLexa PlatformTM’s ability to fight bacterial growth will enable the innate immune system to focus on optimal healing rather than fighting post-procedure infection.
Finally, we intend to explore the use of the BioLexa PlatformTM in connection with diabetic foot ulcers. We believe that the BioLexa PlatformTM‘s ability to fight bacterial growth will help initiate and/or improve chronic diabetic wound healing as well as accelerate the healing of diabetic wounds with S. aureus.
Hoth has also licensed exclusive rights to certain patented technology from the University of Cincinnati for use in determining the risk that a patient will develop allergies to peanuts, milk and other foods as well as predict propensity for eczema. Hoth’s overall goal is to develop and make ready for commercialization a family of genetic screening tests based on the licensed technology.
The BioLexa Platform is a proprietary, patented antimicrobial therapy.
The Platform is based on cutting-edge scientific research from Univ. of Cincinnati (PNAS 2008, PNAS 2013, Biochemical J. 2017, Protein Science 2017).
BACKGROUND:
Centers for Disease Control data indicates that “biofilms” are implicated in over 2/3 of all skin infections. Biofilms are specialized bacterial colonies that are resistant to antibiotics and immune system responses. Moreover, staph bacteria require zinc to form the biofilms that allow the bacterial colonies to grow and resist treatment.
The BioLexa Platform is a synergistic combination of a zinc chelator and an antibiotic that prevents biofilms from forming, leaving the bacteria susceptible to elimination by the antibiotic.
BACTERIAL BIOFILMS: A MAJOR CHALLENGE
Biofilms are specialized colonies of bacteria that adhere to a surface and to one another. The bacteria growing in a biofilm are highly resistant to antibiotics and immune responses. As a result staph biofilms cause recurrent, hard to treat infections.
ZINC & STAPH BIOFILMS
Zinc is required for the formation of staph biofilms
The Staph biofilms form when thread-like thread-like proteins (Aap or SasG) on the bacterial surface stick to one another holding the cells together. The Herr Lab, run by Dr. Andrew Herr at the University of Cincinnati discovered that these proteins only become adhesive when exposed to zinc ions.
The BioLexa Platform traps all the zinc ions by adding a chelator called DTPA, which prevents Staph biofilm formation. In pre-clinical testing on animals, the BioLexa Platform showed impactful results.
HOTH THERAPEUTICS INTENDS TO PURSUE A 505(B)(2) REGULATORY PATHWAY.
The FDA allows some of the safety and efficacy information on active ingredients(s) to come from studies not conducted by Hoth. Because Hoth can rely on the historical data, we should have a much shorter time and cost to get BioLexa FDA approved, as compared to standard 505(B)(1) approval.
Source: https://hoththerapeutics.com/
FN Media Group LLC (FNMG) owns and operates FinancialNewsMedia.com (FNM) which is a third party publisher that disseminates electronic information through multiple online media channels. FNMG’s intended purposes are to deliver market updates and news alerts issued from private and publicly trading companies as well as providing coverage and increased awareness for companies that issue press to the public via online newswires. FNMG and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. The companies that are discussed in this release may or may not have approved the statements made in this release. Information in this release is derived from a variety of sources that may or may not include the referenced company’s publicly disseminated information. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. While this information is believed to be reliable, such reliability cannot be guaranteed. FNMG disclaims any and all liability as to the completeness or accuracy of the information contained and any omissions of material fact in this release. This release may contain technical inaccuracies or typographical errors. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. Investment in the securities of the companies discussed in this release is highly speculative and carries a high degree of risk. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. This release is not without bias, and is considered a conflict of interest if compensation has been received by FNMG for its dissemination. To comply with Section 17(b) of the Securities Act of 1933, FNMG shall always disclose any compensation it has received, or expects to receive in the future, for the dissemination of the information found herein on behalf of one or more of the companies mentioned in this release. For current services performed FNMG has been compensated forty six hundred dollars for Hoth Therapeutics, Inc. for coverage of current news by a non-affiliated third party. FNMG HOLDS NO SHARES OF Hoth Therapeutics, Inc.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.